Program Overview
Target Audience
Learning Objectives
Program Faculty
Accreditation Statement
Credit Designation Statement
Disclosure of Conflicts of Interest
Instructions for Participation and Credit
Disclosure of Unlabeled Use
Disclaimer
Program Overview
The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 21st AIDS Conference (AIDS 2016). This program consists of three components: (1) CME Internet Symposium: AIDS 2016 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) Rapid-Fire Review of AIDS 2016: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (3) From Conference to Clinic: Reviewing and Applying Data From AIDS 2016: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.
The CME Internet Symposium: AIDS 2016 Expert Review will feature five HIV experts reviewing and discussing key presentations on antiretroviral therapy presented at AIDS 2016. The review and discussion will focus on HIV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations, therapies in development, epidemiology, and diagnosis and clinical management of specific patient populations. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All online components of the program can be accessed at www.viraled.com.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AIDS 2016 and it is not sanctioned by the organizers of AIDS 2016.
Target Audience:
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
Learning Objectives:
After completing this activity, the participant should be better able to:
- Use in a clinical setting findings from key new studies on HIV/AIDS diagnosis, management and treatment presented at AIDS 2016
- Employ the current treatment paradigms for HIV/AIDS, including those supported by studies and data presented at AIDS 2016, to improve patient care
- Discuss with patients and colleagues the studies and data on newer therapies for HIV/AIDS presented at AIDS 2016 and use that discussion to decide on appropriate planning of therapy for patients with HIV/AIDS
Release Date: July 29, 2016
Expiration Date: July 29, 2017
Estimated time to complete this program: 2 hours
Media: Internet
Program Faculty:
José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain
|
Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany
|
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine
at the University of Pennsylvania
Philadelphia, Pennsylvania
|
Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
|
Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom |
Renslow Sherer, MD
Professor of Medicine,
Section of Infectious Diseases and Global Health,
University of Chicago
Chicago, Illinois
|
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to provideing its learners
with high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commerical interest.
Jose Arribas, MD
- Consulting Fees: ViiV, Janssen, Abbvie, BMS, Gilead
Ian Frank, MD
- Consulting Fees: Gilead
- Contracted Research: ViiV/GSK
Graeme Moyle, MD
- Consulting Fees: Tobira, BMS, Gilead, Merck
Juergen Rockstroh, MD
- Consulting Fees: Abbott, Abbvie, BMS, Cipla, Gilead, Janssen, Merck, ViiV
- Contracted Research: Gilead
Paul Sax, MD
- Consulting Fees: Abbvie, BMS, Gilead, Merck, ViiV
- Contracted Research: Gilead, BMS, ViiV
Renslow Sherer, MD
- Consulting Fees: Gilead, Janssen
The planners and managers reported the following financial
relationships or relationships to products or devices they or their
spouse/life partner have with commercial interests related to the
content of these CME activities:
The following PIM staff serve as clinical content reviewers and/or
participate in planning CME/CE activities in a manner that may affect
content:, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison,
PharmD; Samantha Mattiucci, PharmD, CHCP; Jan Shultz, RN, MSN, CHCP
and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their
spouse/life partner do not have any financial relationships or
relationships to products or devices with any commercial interests
related to the content of this CME/CE activity of any amount during the past 12 months.
Instructions for Participation and Credit:
There are no fees for participating and receiving CME credit for this activity. During the period, July 29, 2016 through July 29, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If
you wish to received acknowledgment of completing this activity, please
complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 11286.
Upon registering and successfully completing the post-test with a score
of 70% or better and the activity evaluation, your certificate will be
made available immediately. Processing credit requests online will
reduce the amount of paper used by nearly 100,000 sheets per year.
Disclosure of Unlabeled Use:
This
educational activity may contain discussion of published and/or investigational
uses of agents that are not indicated by the FDA. The planners of this activity
do not recommend the use of any agent outside of the labeled indications.
The
opinions expressed in the educational activity are those of the faculty and do
not necessarily represent the views of the planners. Please refer to the
official prescribing information for each product for discussion of approved
indications, contraindications, and warnings.
Disclaimer:
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
|